Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,187Revenue $M1,212Net Margin (%)-36.7Z-Score10.2
Enterprise Value $M20,486EPS $-2.0Operating Margin %-74.5F-Score3
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-80.5Higher ROA y-yY
Price/Book17.910-y EBITDA Growth Rate %0Quick Ratio3.7Cash flow > EarningsY
Price/Sales24.95-y EBITDA Growth Rate %0Current Ratio3.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-19.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-32.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M236ROI % (ttm)-31.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXJohn Burbank 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 88.9928%Sold Out0
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 88.9928%Sold Out0
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 88.9912%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 88.9912%New holding, 10000 sh.10,000
VRTXJohn Burbank 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 88.9912%New holding, 2872 sh.2,872
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 88.9928%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 88.9912%Add 19%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 88.9921%Add 140.58%5,990,000
VRTXDaniel Loeb 2012-12-31 Sold Out -0.77%$38.88 - $59.42
($46.08)
$ 88.9993%Sold Out0
VRTXJohn Burbank 2012-12-31 Sold Out -0.38%$38.88 - $59.42
($46.08)
$ 88.9993%Sold Out0
VRTXDaniel Loeb 2012-09-30 Add0.22%$48.38 - $59.07
($53.5)
$ 88.9966%Add 40%700,000
VRTXJohn Burbank 2012-09-30 Reduce-0.09%$48.38 - $59.07
($53.5)
$ 88.9966%Reduce -25%150,000
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 88.9966%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 88.9966%Sold Out0
VRTXDaniel Loeb 2012-06-30 Buy 0.85%$35.75 - $65.62
($50.92)
$ 88.9975%New holding, 500000 sh.500,000
VRTXJohn Burbank 2012-06-30 Buy 0.38%$35.75 - $65.62
($50.92)
$ 88.9975%New holding, 200000 sh.200,000
VRTXJoel Greenblatt 2012-06-30 Buy 0.08%$35.75 - $65.62
($50.92)
$ 88.9975%New holding, 20025 sh.20,025
VRTXJohn Hussman 2012-06-30 Sold Out -0.93%$35.75 - $65.62
($50.92)
$ 88.9975%Sold Out0
VRTXGeorge Soros 2012-06-30 Reduce-0.05%$35.75 - $65.62
($50.92)
$ 88.9975%Reduce -44%112,000
VRTXJean-Marie Eveillard 2012-06-30 Sold Out -0.02%$35.75 - $65.62
($50.92)
$ 88.9975%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRTX Vanguard Health Care Fund 2014-06-3011,807,50052.9+1.54%
VRTX John Burbank 2014-06-30000Sold Out
VRTX George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2014-08-20Sell5,200$91.51-2.75view
BOGER JOSHUA SDirector 2014-08-13Sell5,200$881.13view
BOGER JOSHUA SDirector 2014-08-06Sell5,200$86.542.83view
ALTSHULER DAVIDDirector 2014-07-31Sell5,000$89.59-0.67view
Silva Paul MSVP & Corp Controller 2014-07-31Sell2,027$88.970.02view
BOGER JOSHUA SDirector 2014-07-30Sell5,200$92.17-3.45view
Riley Wayne JosephDirector 2014-07-15Sell4,800$96.65-7.93view
Horton Kenneth LEVP & Chief Legal Officer 2014-07-01Sell30,134$95.22-6.54view
ULLIAN ELAINEDirector 2014-07-01Sell5,000$95.21-6.53view
Sachdev AmitSVP, Global Gov. Strategy 2014-06-24Sell42,250$98.03-9.22view

Press Releases about VRTX :

    Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
    Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
    WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
    Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
    Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
    Vertex Could Climb On New Drug, VX-222 Success Apr 21 2012 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Columbia Management Fourth Quarter Letter with Comments on SWK, AGCO, CE, MCP, VRTX, DOLE, F, HAS, A Apr 10 2012 
    Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
    4 Pharmaceuticals with Long and Short Opportunities Feb 28 2012 


    More From Other Websites
    Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus Aug 20 2014
    SEC probing Valeant, Ackman's hostile Allergan bid - WSJ Aug 14 2014
    Vertex leads S&P 500, King drops on outlook Aug 13 2014
    Vertex to end sales of hepatitis C drug Incivek Aug 13 2014
    Shares Rise, as Biotech Gains Offset Listless Retail Sales Aug 13 2014
    From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate Aug 12 2014
    GW Pharma, Insys Face Off In Cannabis Drug Space Aug 08 2014
    A Healthy Biotech ETF Aug 08 2014
    VERTEX PHARMACEUTICALS INC / MA Financials Aug 08 2014
    Today's Stocks Driving Success For The Health Care Sector Aug 08 2014
    Wall Street Transcript Interview with Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics... Aug 08 2014
    Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the... Aug 07 2014
    Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress Aug 06 2014
    Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations Jul 31 2014
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 10-Q, Quarterly Report Jul 31 2014
    4:18 pm Vertex Pharm receives European approval for KALYDECO (ivacaftor) in eight non-G551D gating... Jul 31 2014
    Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations Jul 31 2014
    Vertex Pharmaceuticals Posts Wider Q2 Loss, Maintains View Jul 30 2014
    Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and... Jul 29 2014
    Vertex Pharma posts bigger 2Q loss Jul 29 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide